Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody for mycosis fungoides (MF) and Sézary syndrome (SS), can trigger immune-mediated complications, such as rashes or endocrine disorders. Rheumatological manifestations are rare. OBJECTIVES: To describe cases of inflammatory rheumatism (IR) induced or worsened by MOGA in MF/SS patients. METHODS: A retrospective study collected cases of IR (polymyalgia rheumatica [PMR], rheumatoid arthritis [RA], spondylarthritis, or unclassified IR) in MF/SS patients treated with MOGA across centers of the French Cutaneous Lymphomas Group. Clinical, biological, and imaging data were analyzed. RESULTS: Eleven patients (7 men, 4 women; median age: 72 years) developed IR during (10/11) or soon after (1/11) MOGA treatment. Symptoms included joint pain, stiffness, and functional impairment. All had biological inflammatory syndrome, synovitis on ultrasound, and no autoantibodies. PET-CT confirmed hypermetabolism consistent with intense joint inflammation (SUV=8.0). Management with systemic corticosteroids ± methotrexate led to remission in most cases. MOGA had to be discontinued in 8 patients, with lymphoma control maintained in 6. CONCLUSIONS: MOGA may induce disabling IR, potentially via CCR4+ regulatory T-cell depletion. Early recognition and treatment with corticosteroids ± methotrexate are essential, though MOGA discontinuation may be required.
Source: Joint Bone Spine
Institutions: Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire Henri-Mondor, Inserm, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes, Université de Nantes, Nantes Université, Centre Hospitalier de Roubaix, Centre Hospitalier Universitaire de Tours, Centre Hospitalier du Mans, Centre Hospitalier Universitaire de Reims, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Centre Hospitalier Universitaire de Poitiers, Institut Jules Bordet, Hôpital Avicenne, Université de Montpellier, Université de Bordeaux, BoRdeaux Institute of onCology, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Epidemiology in dermatology and evaluation of therapeutics
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,020
OpenAlex ID: W7221324071